Mukul Agrawal Gains Over 3x Vijay Kedia’s Profit in This Small-Cap Multibagger Stock in Just One Day: Mukul Agrawal Gains Rs 33.92 Crore While Vijay Kedia Gains Rs 11.02 Crore

The benchmark indices, Nifty50 and Sensex, traded lower on Tuesday, with the Nifty 50 declining 0.78 per cent to 23,914.90 amid broad-based selling pressure. Despite the weak market sentiment, Neuland Laboratories' share price surged 4.92 per cent to Rs 18,072, outperforming the broader market.
 

Pharma Stocks In Focus After US Turns To Indian Drugmakers

Pharma stocks witnessed buying interest after reports suggested that the US Food and Drug Administration (FDA) has reached out to Indian pharmaceutical manufacturers to help address a shortage of critical cancer medicines in the United States. According to media reports, the US is facing low inventories of certain oncology drugs and is looking at Indian companies to support supply requirements.

The development has boosted investor sentiment towards Indian pharmaceutical companies, as any increase in export opportunities could support future revenues and capacity utilisation for manufacturers with strong regulatory and manufacturing capabilities.

Neuland Laboratories Shareholding Pattern

According to the latest shareholding pattern for March 2026, Ace Investor Mukul Mahavir Agrawal held 4,00,000 equity shares, representing a 3.12 per cent stake in Neuland Laboratories. With the stock rising Rs 848 during Tuesday's session, the value of his holding increased by approximately Rs 33,92,00,000 crore in a single day.

Meanwhile, Kedia Securities Private Limited, associated with veteran investor Vijay Kedia, held 1,30,000 equity shares, representing a 1.01 per cent stake in the company. Based on the day's gain of Rs 848 per share, the value of its holding increased by approximately Rs 11,02,40,000 during the trading session.

Institutional ownership in the company remains strong. Foreign Institutional Investors (FIIs) held 20.46 per cent stake as of March 2026, while Domestic Institutional Investors (DIIs) increased their holding to 15.84 per cent, compared with 14.72 per cent in the December 2025 quarter.
Also Read - Rs 10,166 Crore Order Book: Navratna PSU Secures Rs 3,34,51,69,491 Ministry Of Railways Contract For e-Office Upgrade Project

Neuland Laboratories Share Price Performance

Neuland Laboratories has delivered robust returns across multiple time periods. The stock has gained 7.94 per cent in the last one month, 18.02 per cent over the past six months and 46.97 per cent during the last one year.

The company currently commands a market capitalisation of approximately Rs 23,203 crore, making it one of the prominent players in India's pharmaceutical manufacturing space.

About Neuland Laboratories

Neuland Laboratories Ltd is a leading pharmaceutical company focused on the manufacturing of active pharmaceutical ingredients (APIs), custom manufacturing solutions and speciality pharmaceutical products. The company serves global pharmaceutical innovators and generic drug manufacturers across regulated and emerging markets.

Neuland has established strong capabilities in complex chemistry, process development and commercial-scale manufacturing. The company exports products to several international markets, including the United States, Europe and Japan, and has built a reputation for quality, regulatory compliance and high-value pharmaceutical manufacturing.

What are your views on Neuland Laboratories and the potential opportunity arising from the US cancer drug shortage? Share your thoughts in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.